Perrigo gets FDA nod for generic Penlac nail-fungus treatment

Sept 19 (Reuters) - Perrigo Co (PRGO.O) said it received final approval from U.S. health regulators for Ciclopirox topical solution, a generic version of Sanofi-Aventis' (SASY.PA) Penlac nail-fungus treatment.

The generic drugmaker said brand sales for Penlac for the last 12 months ending August were $92 million, citing data from publisher Wolters Kluwer. (Reporting by Neha Pathania in Bangalore)